Compounded Tirzepatide in 2026: Is It Legal, and Is It Safe?

If you've searched for compounded tirzepatide lately, you've seen two very different stories. Telehealth ads say "personalized" tirzepatide is still easy to get for a fraction of the brand price. FDA says copying an approved drug that isn't in shortage isn't allowed. I've spent more than 30 years watching the hair-loss market go through the same cycle: a real drug, a cheaper look-alike, then a crackdown. My aim here is to explain what's legal right now, where the safety concerns come from, and how to tell a legitimate prescription from a workaround.

What compounded tirzepatide is, and why it existed

Tirzepatide is the active ingredient in Eli Lilly's Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management and obstructive sleep apnea). It acts on two gut-hormone receptors, GIP and GLP-1. Compounding means a pharmacy mixes its own version from raw drug substance, outside the FDA approval process.

Compounders were allowed to make tirzepatide only because FDA listed it as in shortage starting in late 2022. While a drug is on the shortage list, federal law relaxes the rules against copying it. That exception was always meant to be temporary.

Is compounded tirzepatide legal in 2026?

For routine use, no. Here's the timeline as FDA describes it:

The bottom line is that neither kind of compounder has a general green light. A 503B outsourcing facility can't use bulk tirzepatide at all, because it's on neither the shortage list nor the 503B bulks list. A 503A pharmacy can't regularly make what FDA calls "essentially a copy" of a commercially available drug.

The "essentially a copy" test, in plain English

In its April 2026 update, FDA said it may treat a compounded product as essentially a copy if it has the same active ingredient, in the same or an easily substituted strength, given by the same route. Tweaking the strength slightly or adding a vitamin doesn't automatically get around the rule. The presumption can be overcome only when the prescriber documents a significant clinical difference for that specific patient. Legal analysts list the usual examples: an allergy to an ingredient in the approved product, a concentration that isn't commercially available, or a required change in dosage form. Patient preference and saving money aren't enough.

FDA also said it generally won't act against a 503A pharmacy that fills four or fewer prescriptions of an essentially-copied product in a calendar month. That's a small allowance for occasional needs. A telehealth company shipping thousands of vials a month doesn't fit within it.

What the new HHS peptide policy does (and doesn't) change

This is where people are getting confused. In late October 2026, HHS announced enforcement discretion that lets 503A pharmacies compound six peptides while FDA writes formal rules: BPC-157, TB-500, KPV, MOTS-c, epitalon and semax. I explain that policy in Are Peptides Legal?

Tirzepatide isn't on that list. GLP-1 drugs are FDA-approved products that are back in full supply, so they fall under different rules. If a provider cites "the new peptide rules" to justify compounded tirzepatide, take that as a red flag.

Safety: what FDA and clinicians are actually seeing

FDA doesn't review compounded drugs for safety, effectiveness or quality before they reach patients. As of May 31, 2026, the agency had received more than 730 adverse event reports for compounded tirzepatide, and it believes the true number is higher. The problems it describes fall into a few groups:

• Dosing errors. Most compounded tirzepatide comes in multidose vials, so patients draw up their own amount. FDA has seen errors by patients and by clinicians, some leading to hospitalization. Stanford Medicine notes cases of doses 10 to 20 times the intended amount.
• Add-ins. Many compounders add B12, B6, glycine, niacinamide or carnitine. None of these has been shown to improve weight-loss outcomes. Stanford cites a 2026 study finding that combining tirzepatide with B12 can create a new molecule that isn't in the approved drug, with unknown clinical effects.
• Potency and labeling. Some products contain more or less drug than the label states. Fragile peptides can also break down in storage without any visible sign.
• Fraud. FDA has found compounded GLP-1 products carrying false label information, including the names of pharmacies that don't exist.

FDA is also policing the next wave. In 2026 it sent warning letters to telehealth companies and ingredient suppliers selling retatrutide, an investigational drug that can't legally be compounded at all.

A five-point check before you trust any tirzepatide offer

None of the top-ranking pages on this topic gives readers a practical way to vet an offer, so here's mine:

1. Is there a real prescriber evaluation? A legitimate provider reviews your history and medications. Ask whether they want recent labs; my bloodwork guide covers the basics. If the only step is a checkout page, walk away.
2. Is the medical reason written down? If you're getting a compounded product, the prescriber should be able to name the specific clinical reason you can't use the approved drug.
3. Who made it? Get the pharmacy's name and state license, and for a 503B facility, check that it's registered with FDA. Avoid anything labeled "for research use only" or "not for human consumption."
4. What else is in the vial? Ask for the full ingredient list. Proprietary "blends" and unusual forms such as drops or lozenges add unknowns without proven benefit.
5. Who supervises you? Your plan should include follow-up and clear guidance on warning signs: severe abdominal pain that spreads to the back, signs of dehydration, or stomach symptoms that keep getting worse.

The approved route is cheaper than it used to be

Price is the main reason people turn to compounding, and the gap has narrowed. Lilly now sells Zepbound directly to self-pay patients through LillyDirect. Its posted prices start at roughly $299 a month for the starting strength and run up to $449 for higher strengths, provided refills are on time. Eligibility rules apply, and Lilly can change the terms. That still isn't cheap, but you get an FDA-approved product with a known strength and a supply chain you can verify. Your clinician can also check your insurance coverage and other cost-saving programs.

If you're already on a compounded product, don't stop or switch abruptly, especially if you're taking it for diabetes. Clinicians quoted by Stanford advise working with a prescriber on the transition, because the true strength of what you've been taking may be uncertain. For more on how weight-loss drugs fit with other peptides, see our assessment.

Bottom line: The case for compounded tirzepatide ended with the shortage. Today it's legitimate only for a narrow, documented medical need, and FDA appears ready to make the 503B ban permanent. If someone offers you "personalized" tirzepatide with no medical reason on paper, you're the one taking the risk. The approved product, prescribed by a licensed clinician who monitors you, is the safer choice.